New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announces promising data on its Nu.Q® assay presented at the International Society for Apheresis meeting. The study conducted with Santersus AG shows that the Nu.Q® assay effectively monitors the removal of Neutrophil Extracellular Traps (NETs) in a pig model of sepsis. Results indicate that this innovative treatment can remove up to 99% of circulating NETs, potentially offering new avenues for treating various diseases, including sepsis, COVID-19, and cancer. Further studies are underway for human trials.

Positive

• Data shows Nu.Q® assay effectively monitors NET removal, indicating broad applicability in treating diseases.
• Santersus' treatment demonstrates the capability to remove up to 99% of circulating NETs, improving well-being in treated animals.
• The upcoming human trials with Santersus signal potential advancements in treatment options.

Negative

• None.

AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with Swiss-based Santersus AG, a private company that has an abstract released today at the International Society for Apheresis meeting (e-ISFA), which is being held virtually this year.

The poster presentation entitled "Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis" given by Dr. Andrew Aswani, Consultant in Intensive Care Medicine & Anesthesia at a leading London Hospital and Chief Medical Officer of Santersus AG, includes data showing that Nu.Q^® is an effective method for monitoring Santersus' highly selective plasmapheresis treatment targeting Neutrophil Extracellular Traps ("NETs") in sepsis.

Commenting on the data Dr. Aswani said, "Our data indicated that the Nu.Q^® assay may have wide applicability to monitor the treatment of diseases with a NET component and potentially may also be used for patient selection. This is especially important given the wide range of diseases where NETosis plays a role such as COVID-19, sepsis, autoimmune diseases and cancer. Santersus has already begun the next phase of studies that are also using Volition's Nu.Q^® assays, including our first human trial, and we look forward to sharing the results in the coming months."

Dr. Jake Micallef, Volition's Chief Scientific Officer added, "Santersus' highly selective plasmapheresis treatment is demonstrably effective in the removal of up to 99% of circulating NETs from animals in septic shock as measured by our Nu.Q^® NETs assay. The results also show that the treatment leads to a stabilization of NETs in circulation and a great improvement in the well-being of the treated animal. This is the first study reported to use Volition's simple, low-cost Nu.Q^® immunoassays to monitor response to a treatment."

To watch a short video of Dr. Jake Micallef commenting on this study click https://youtu.be/5sm3Z6dmr6w.

To view the presentation given by Dr. Aswani click here or download the poster here.

About the Study

NETs are made of nucleosomes and are associated with sepsis. Santersus investigated the removal of NETs from the circulation of a pig model of sepsis using the Santersus NucleoCapture therapeutic plasmapheresis method and monitored the therapy using Volition's 45-minute, automated Nu.Q^® immunoassay as a surrogate measure for circulating NET levels.

Plasmapheresis treated and untreated animals were monitored by a variety of physiological and biochemical parameters including lactate levels (an indicator of sepsis severity), vasopressor requirements (septic shock leads to low blood pressure which is ameliorated by treatment with vasopressors) and urine output (urine output falls during septic shock).

Nu.Q® immunoassays successfully monitored the rise in NETs caused by sepsis. They also demonstrated that the plasmapheresis treatment removed almost all (up to 99%) of nucleosomes from treated blood and that untreated sepsis led to a high and continuously rising level of circulating NETs. Finally, Santersus also demonstrated that the plasmapheresis treatment successfully prevented this rise in NETs leading to a lower and stable level of circulating NETs.

For further details please contact mediarelations@volition.com.

About Santersus

Santersus AG is a Zurich-based Innovative Therapeutic Apheresis company focused on cleansing patient blood of NETs using the company's patented first-in-class "NucleoCapture" technology. Santersus aims to revolutionize how we can control the human immune and inflammatory response to disease by transformative, lifesaving, highly selective blood purification using the NucleoCapture method in the treatment of many diseases including COVID-19, sepsis, autoimmune diseases and cancer.

For more information about Santersus, visit Santersus' website at www.santersus.com or email info@santersus.com

About Volition

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics^TM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

For more information about Volition, visit Volition's website volition.com or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor, Volition mediarelations@volition.com +44 (0)7557 774620	Scott Powell, Volition investorrelations@volition.com +1 (646) 650 1351
Jen Lewis, Pegasus jen.lewis@thisispegasus.co.uk +44 (0)7809 867943	Joseph Green, Edison Advisors jgreen@edisongroup.com +1 (646) 653 7030

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's blood-based diagnostic and prognostic tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-data-demonstrates-nuq-is-effective-in-monitoring-treatment-of-sepsis-301249241.html

SOURCE VolitionRx Ltd

FAQ

What are the recent findings related to VNRX and sepsis treatment?

VolitionRx's Nu.Q® assay has demonstrated effectiveness in monitoring Neutrophil Extracellular Traps (NETs) removal in sepsis, showing potential for broad disease applications.

How effective is the Nu.Q® assay in monitoring sepsis treatment?

The assay can monitor the removal of up to 99% of circulating NETs, which is crucial for managing sepsis in the studied pig model.

What is the significance of the study presented at the International Society for Apheresis for VNRX?

The study's results could lead to advancements in treatments for various diseases, including sepsis and cancer, enhancing VNRX's market potential and innovation status.

What future studies are planned for VNRX's Nu.Q® assay?

Santersus AG is set to initiate human trials using the Nu.Q® assays, with results expected in the coming months.